ALBERT

Description: The spawning biomass of Pacific herring, Clupeapallasi, estimated from spawning-ground surveys inSan Francisco Bay declined to 41,000 tons this season.This was the second consecutive year that the SanFrancisco Bay herring population estimate has declined.In Tomales Bay, the 1991-92 season spawning biomassestimate, including the catch of 24 tons from Bodega Bay,was 1,238 tons. This was the third consecutive seasonthat the Tomales-Bodega area herring population hasincreased.The 1991-92 Humboldt Bay herring spawning biomass estimateof 225 tons, was nearly half of last season's estimate of400 tons.December and January were the peak months of spawningactivity in all areas surveyed.In San Francisco Bay, the first major spawn since the 1981-82 season occurred in the Sausalito area, and the Oakland-Alameda area accounted for 50% of all spawning activity.A total of 3.5 million m2 of eelgrass, Zostera marina,was measured in Tomales Bay this season. The eelgrassdensity declined in most beds this season. (46p.)

Description: Statewide Pacific ocean shrimp, Pandalus jordani, landings totaled 2,033.1 mt (4,472,749 lb) down 204.6 mt (450,108 lb) from the 1979 catch of 2,237.7 m t (4,922,857 lb). The 1980 landings are the lowest since 1976 when 1,545.5 mt (3,400,191 lb) were landed. Area A (Eureka-Crescent City) landings dropped to 1,234 mt (2,716,147 lb) from 1,842.5 mt(4,053,605 lb) landed during the previous season. Area B-1 (Fort Bragg) landings totaled 79.3 mt (174,395 lb) from catches made during the last 9 days of the season. Only 100 lb were reported caught in Area B-2 (Bodega Bay). Record landings of 719.1 mt (1,582,107 lb were made in Area C (Morro Bay-Avila), surpassing the previous record of 391 mt(864,667 lb) landed in 1979. In Area A a record 80 vessels, 34 double-rigged and 46 single-rigged, made shrimp deliveries during the season. Average catch per hour was a very low .ll mt (234 lb) and .20 mt (446 lb) for single-rig and double-rig vessels, respectively. In Area C averagecatch per hour was .25 mt (557 lb) and .21 mt (462 lb) for single-rig and double-rig vessels, respectively. Area A shrimp catches were dominated by 1-year-old shrimp in percent by number throughout the season. The age composition in Area C shifted from predominately 2-year-old shrimpin April, May, and June to predominately 1-year-old shrimp for the remainder of the season. Area A was closed for one month from June 1 to July 1 because closure criteria of less than .16 mt (350 lb) per hour for two consecutive weeks was met and year class composition exceeded 70% of year-old shrimp. The season was closed for the year on August 25 whenthe catch per hour and percent 1-year-old shrimp criteria was exceeded again.(22pp.)

Description: Statewide Pacific ocean shrimp, Pandalus jordani, landings totaled 13,163,243 lb, down about 2.5 million lb from the 1977 record catch of 15,639,584 lb. However, the 1978 landings were still the second highest on record. Area A (Eureka-Crescent City) landings were the secondhighest in history with landings of 11,101,895 lb. Landings of 2,061,348 lb in Area B-1 (Fort Bragg) broke all existing records for the bed. The previous record was 799,722 lb landed in 1961. No landings were reported for Areas B-2 (Bodega Bay) and C (Avila-Morro Bay). In Area A the average catch per hour for the season for single-rig vessels was 581 lb and 862 lb for double-rig vessels. Area B-1 averagecatch per hour was 819 lb and 1,069 lb per hour for single-rig and double-rig vessels, respectively. Two-year-old (1976 year class) shrimp dominated the catches during the first three months in Area A and throughout the season in Area B-1. One-year-old (1977 year class)shrimp dominated the catches in Area A from July to the end of the season. Catches during the first part of October in Area A fell below the established criteria for keeping the season open. This necessitated closing the season two weeks early. (16pp.)

Description: The progress of the research program in the year 1975 is presented. In addition to a report of project studies, discussions of program development, research procedures, and cooperative research efforts are included. The crab critical stage project studies included distribution and relative abundance of larvae and juvenile crabs in the Gulf of the Farallones, San Pablo Bay and San Francisco Bay. Several fish species were identified as crab predators, genetic structure of Dungeness crab populationswere investigated, and growth rates of juvenile crabs were determined. The crab environment project collected historical and recent data on parameters of oceanographic factors including temperatures, salinities, currents, upwelling, sea level, and river flows into the bays and ocean. Environmental toxicant levels in crabs are being determined for a wide spectrum of heavy metals, pesticides, PCB's, and petroleum hydrocarbons.The Marine Culture Laboratory developed techniques for small and large scale culture of crabs from eggs held under controlled conditions to aid in design of laboratory tests of the effects of environmental factors on crab survival. (81pp.)

Description: Statewide Pacific ocean shrimp, Pandalus jordani, landingstotaled 15,639,585 lb, more than triple the 1975 record catch of 4,992,233 lb. Record landings were recorded in Area A (Eureka-Crescent City), Area B-2 (Bodega Ray) with catchestotaling 13,025,844 and 2,028,607 lb, respectively. Area B-1(Fort Bragg) landings totaled 585,133 lb and no landings were reported from Area C (Avila-Morro Bay). In Area A the average catch per hour for the season for single-rig vessels was 1,241 lb and 2,228 lb for double-rig vessels. Area B-2 average catch per hour by the single-rig vessels was 2,536 lb. Two-year-old (1975 year class) shrimp dominated the catches in all areas. The outlook for the 1978 season in all areas is questionable because of the relatively weak showing of the incoming 1977 year class but it might make a significant contribution if abundant and of a marketable slze. (19pp.)

Description: Statewide Pacific ocean shrimp, Pandalus jordani, landings totaled 2,237.7 mt (4,922,857 lb), down 3,745 mt (8,240,386 lb) from the 1978 catch of 5,983.3 mt (13,163,243 lb). The 1979 landings are the lowestsince 1976 when 1,545.5 mt (3,400,191 lb) were landed. Area A (Eureka-Crescent City)landings dropped to 1,842.5 mt (4,053,605 lb) from 5,046.3 mt (11,101,895 lb) landed during the previous season. No landings were made in Area B-1 (Fort Bragg). Only 2.0 mt (4,385 lb) were reported caught in Area B-2 (Bodega Bay). Record landings of 393.1 mt(864,867 lb) were made in Area C (Morro Bay-Avila), surpassing the previous record of 90.4 mt (199,000 lb) landed in 1953. In Area A a record 71 vessels, 34 double-rigged and 37 single-rigged, shrimped during theseason. Average catch per hour was a low .15 mt (338 lb) and .22 mt (490 1b) for single-rig and double-rig vessels, respectively. In Area C average catch per hour was .23 mt (508 lb) and .42 mt (924 lb) for single-rig and double-rig vessels, respectively. Area A shrimp catches were dominated by 1-year-old shrimp throughout most of the season. Theage composition in Area C shifted predominately from 2-year-old shrimp in May and June to predominately 1-year-old shrimp in July, August, October, and November. Area A was closed for one month from July 15 toAugust 15 because closure criteria of less than .16 mt (350 lb) per hour for two consecutive weeks was met and year class composition exceeded 70% of 1-year-old shrimp. The season was closed October 14 when the catch per hour criterion was exceeded again. (18pp.)

Description: INTRODUCTION: R-CHOP is effective for diffuse large B-cell Lymphoma (DLBCL), but many patients (Pts) relapse or have refractory disease, likely due to inherent biologic differences in DLBCL subtype. Activated B-Cell (ABC) subtype DLBCL signals through Nuclear Factor-κ-B (NF-κB) and is more likely to display treatment failure than DLBCL arising from the germinal center (GC). Proteasome inhibitors disrupt NF-κB signaling, but randomized trials have failed to demonstrate clinical benefit of adding bortezomib to R-CHOP for the treatment of non-GC DLBCL. Carfilzomib (Car) displays superior clinical activity relative to bortezomib in plasma cell neoplasms and, while occasionally associated with cardiac events, does not have dose-limiting neuropathy. To explore the safety and efficacy of Car in upfront treatment of DLBCL, we initiated a phase I/II clinical trial of Car + R-CHOP and report the phase I results. METHODS: 24 adult (age ≥ 18) Pts with untreated de novo or transformed DLBCL, adequate organ function and performance status were enrolled. During 3 x 3 dose escalation, Car was given at 20 mg/m2 on days 1 and 2, with R-CHOP on day 2 for 6 cycles (n = 6). Due to grade 4 thrombocytopenia, the protocol was amended to administer Car at a dose (in mg/m2) of 20 on days 1 and 2 of cycle 1 with rituximab (R) on day 2 and CHOP on day 3, followed by a Car dose of 20 (n=3), 27 (n=3), 36 (n=3), 45 (n=3) and 54 (n = 6) on days 1 and 2 of cycles 2-6. All Pts received pegfilgrastim the day after CHOP and zoster prophylaxis with acyclovir x 6 months post treatment. Echocardiograms were obtained at baseline and at conclusion of therapy to assess the cardiac safety of combining Car with anthracycline. Interim response assessments with CT +/- PET were performed after cycle 3 and end-of-treatment response assessments were uniformly captured with PET. RESULTS: The median age was 57 (range 24-77) years old. 63% of patients were female. Stage at diagnosis was I-II (58%) or III-IV (32%). The majority of Pts had ECOG performance status of 0-1 (88%). B symptoms were present in 21% of Pts and 54% had an increased LDH at diagnosis. 29% had 〉1 extranodal site. IPI score was 0-1 (50%), 2 (21%) or 3-4 (39%). For this phase I dose escalation study, eligible Pts included primary mediastinal lymphoma (n = 1) and DLBCL of GC (n = 9), non-GC (n = 13) and unknown (n = 1) Hans algorithm subtypes. Hematologic adverse events (AEs) included 60 grade 1/2, 27 grade 3 and 16 grade 4 AEs. Grade 3/4 hematologic toxicities included neutropenia (n=14), thrombocytopenia (n = 6) anemia (n = 6), with only 4 cases of grade 3 febrile neutropenia. Grade 3/4 non-hematologic AEs were generally consistent with known R-CHOP toxicity were notable for: hypertension (n = 2), decreased ejection fraction (n =2), GI hemorrhage (n = 2) dizziness, headache, and syncope (n = 1 each), thromboembolic event (n=1), hyperglycemia (n=2), increased ALT (n=1) and nausea/vomiting (n=2). Compared to age-matched controls, end-of-treatment echocardiograms of CarR-CHOP treated Pts showed no statistically significant additional effect on ejection fraction (EF) [94.8% vs. 90.0% of pre-treatment value, respectively (P = 0.19)] after 6 cycles of treatment and there was no association of change in EF with Car dose (P = 0.61). There were no dose limiting toxicities. As of June 2018, median follow-up among surviving Pts was 16 months. There were 3 deaths during the study period, 2 from lymphoma and 1 from lung cancer. The overall response rate was 92% [75% complete remission (CR), 17% partial remission]. 18-month Kaplan Meier estimates of PFS and overall survival were 77% and 88%, respectively (Figure). There was no significant difference in CR rates or PFS for patients with GC vs. non-GC subtype (P = 0.65 and 0.61, respectively). CONCLUSION: CarR-CHOP is safe at a recommended phase II dose of 20 mg/m2 on day 1 & 2 for cycle 1 followed by 56 mg/m2 for cycles 2-6, without significant excess cardiac effects. Within the limitations of a prospective phase I clinical trial with potential patient selection bias, preliminary efficacy data suggest a high complete metabolic response rate and equivalent outcomes for patients with GC and non-GC subtype. Phase II accrual is ongoing for non-GC DLBCL only and additional correlative studies of the molecular subtype of DLBCL will be incorporated into future analysis. Disclosures Hill: Amgen: Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees. Tomlinson:Foundation Medicine: Consultancy. Caimi:Genentech: Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Research Funding; Celgene: Speakers Bureau; Kite Pharma: Membership on an entity's Board of Directors or advisory committees.

Description: Background Right ventricular (RV) systolic strain has recently demonstrated prognostic value in various cardiovascular diseases. Despite this, the reference range including the lower limit of normal (LLN) and factors associated with RV strain measurements are not well-established. This meta-analysis aimed to determine the mean and LLN of two- (2D) and three-dimensional (3D) right ventricular global (RVGLS), free wall (RVFWLS) and interventricular septal wall (IVSLS) longitudinal strains in healthy individuals and factors that affect strain measurements. Methods In this meta-analysis, Pubmed, Embase and Cochrane databases were searched until 31 July 2020 for eligible studies reporting RVGLS, RVFWLS and/or IVSLS in at least 30 healthy subjects. We pooled the means and LLNs of RV strains by two- (2D) and three- (3D) dimensional echocardiography, and performed meta-regression analyses. Results From 788 articles screened, 45 eligible studies totaling 4439 healthy subjects were eligible for analysis. Pooled means and LLNs with 95% confidence intervals for 2D- RV strains were RVGLS -23.4% (-24.2%, -22.6%) and -16.4% (-17.3%, -15.5%) in 27 studies; RVFWLS -26.9% (-28.0%, -25.9%) and -18.0% (-19.2%, -16.9%) in 32 studies; and IVSLS –20.4% (-22.0%, -18.9%) and -11.5% (-13.6%, -9.6%) in 10 studies, and similar results for 3D- RV strains. Right ventricular fractional area change and vendor software were associated with 2D-RVGLS and RVFWLS means and LLNs. Conclusion We reported the pooled means and LLNs of RV systolic strains in healthy subjects, to define thresholds for abnormal, borderline and normal strains. Important factors associated with RV systolic strains include right ventricular fractional area change and vendor software.